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Abstract
The discovery of lithium’s efficacy as a mood-stabilizing agent revolutionized the treatment of patients
with bipolar disorder and after five decades, lithium continues to be the mainstay of treatment for bi-
polar disorder. Recent research on the molecular mechanism underlying the therapeutic effect of
lithium has focused on how it changes the activities of cellular signal transduction systems, especially
the cyclic AMP and phosphoinositide second-messenger systems. Considerable data suggest that
carbamazepine and valproate (VPA) are an alternative or adjunctive treatment to lithium. VPA, despite
being dissimilar structurally to lithium, shares most of the effects of lithium at the level of protein
kinase C (PKC). Like lithium, VPA reduces the activity of PKC and reduces the protein levels of dif-
ferent PKC isoforms, however the effects of VPA appear to be largely independent of myoinositol.
The long-term efficacy of VPA and lithium in bipolar disorder suggested that modulation of gene
expression might be an important target for these drugs. Both VPA and lithium altered the expression
of the early inducible genes for c-fos and c-jun thus promoting the expression of specific proteins. The
genes known to be regulated by the AP-1 family of transcription factors include genes for various
neuropeptides, neurotrophins, receptors, transcription factors, enzymes, proteins that bind to cyto-
skeletal elements, and cytoprotective proteins such as bcl-2. In conclusion chronic treatment with lithium
and other mood stabilizers, by regulating transcriptional factors, may modulate the expression of
a variety of genes that compensate for aberrant signalling associated with the pathophysiology of
bipolar disorder.
Received 7 October 2002; Accepted 13 November 2002
Key words : Gene expression, lithium, mood stabilizers, second messengers.
Introduction
Manic-depressive illness is a common, severe, chronic
and life-threatening illness, and represents one of
the leading causes of disability worldwide (Mu¨ller-
Oerlinghausen et al., 2002). Several drugs have shown
efficacy in controlling acute manic symptoms (Thase
and Sachs, 2000). These include anticonvulsants,
benzodiazepines, antipsychotics, calcium channel
blockers, as well as lithium. Some of these agents,
particularly the mood-stabilizing anticonvulsants
and lithium are also effective in the prophylactic
management of bipolar disorder.
The three agents with mood-stabilizing properties
supported by the strongest data are lithium, carba-
mazepine (CBZ) and valproic acid. CBZ and valproate
(VPA) are now the first-line therapy for lithium-
resistant or -intolerant patients. Most recently, newer
anticonvulsants such as lamotrigine, gabapentin,
topiramate, and oxcarbazepine have been examined
in preliminary studies as possible alternatives in
the treatment of this disorder (Chengappa et al.,
1999; McElroy et al., 1997; Sporn and Sachs, 1997).
Other newer anticonvulsants that could also have
a role in the treatment of bipolar disorder are tiaga-
bine, vigabatrin, felbamate, but there are still no sys-
tematic reports on their effects in mood disorder
patients.
Understanding the molecular and cellular mechan-
isms by which these drugs achieve their therapeutic
action, especially their shared effects, would represent
a valuable step in clarifying the pathophysiology and
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possibly the pathogenic process that lead to mania and
bipolar depression.
Mechanism of action of mood stabilizers: from
ion transport to second messengers
Early biological theories regarding mechanisms of ac-
tion of mood stabilizers and antidepressants focused
on modulation of neurotransmitter synthesis, release,
turnover and uptake (Lenox et al., 1998). However,
although a number of acute, in-vitro effects of these
agents are well established, their therapeutic effects
are only seen after chronic administration, thereby
precluding any simple mechanistic interpretations
based on acute biochemical effects. In the past decade
the focus has shifted to post-synaptic events, such
as the regulation of signal transduction mechanisms.
More recent studies with lithium and mood stabil-
izers have focused on transcription factors coded
by immediate early genes and regulation of cyto-
skeletal protein function (Lenox and Hahn, 2000). The
search for the mechanisms of action of mood stabil-
izers has been facilitated by a growing appreciation
that rather than any single neurotransmitter system
being responsible for depression or mania, multiple
interacting and overlapping systems are probably in-
volved in regulating mood and that most effective
drugs probably do not work on any particular neuro-
transmitter system in isolation, but rather affect the
functional balance between interacting systems (Chen
et al., 1999a).
In search for a link between the mechanism of ac-
tion of lithium and neurotransmission, the effect of
lithium has been extensively studied on virtually
every neurotransmitter system (Lenox and Hahn,
2000). Chronic lithium has been reported to prevent
behavioural and biochemical manifestations of halo-
peridol-induced dopamine receptor supersensitivity.
The effect of lithium on norepinephrine receptor
binding has been generally inconclusive, however
it has been shown that lithium treatment enhances
receptor subsensitivity following antidepressant treat-
ment and prevents b-adrenergic receptor supersensi-
tivity induced by neurotransmitter depletion. One of
the most consistent observations, in vivo as well as
in vitro, is that b-adrenergic receptor-mediated cAMP
accumulation is decreased by acute lithium treatment.
Preclinical studies have shown that lithium affects
serotonergic transmission at multiple levels resulting
in an enhancement of serotonergic neurotransmission.
Chronic treatment of lithium increases basal and
stimulation-induced serotonin (5-HT) release, more-
over it produces a subsensitivity of presynaptic
inhibitory 5-HT-1A receptors, which can result in a net
increase of 5-HT released per impulse. These findings
provide the neurochemical basis for the clinical ob-
servation of lithium efficacy as an adjunct to anti-
depressants in the treatment of resistant depression.
In plasma and CSF of human subjects as well as
various regions of the rat brain, lithium treatment has
been shown to increase the level of GABA; GABA-B
receptors were found to be increased in the hippo-
campus following chronic treatment with lithium as
well as with anticonvulsant mood stabilizers.
It has been recently reported that lithium acutely
increases synaptic concentrations of glutamate, lead-
ing then, upon chronic administration, to an increase
and stabilization in glutamate uptake transporter
capacity ( Jope, 1999). This effect could mediate a re-
duction and stabilization in excitatory neurotrans-
mission after lithium treatment and may contribute to
a relatively large and diverse group of findings in the
literature indicating that lithium has neuroprotective
effects. This neuroprotective action may be mediated
by increased glutamate uptake, attenuated increases
in intracellular calcium levels associated with excit-
atory neurotransmission, and the recent finding that
lithium up-regulated the anti-apoptotic protein bcl-2
(Chen and Chuang, 1999; Chen et al., 1999b).
Clinical evidence clearly indicates that the thera-
peutic effects of lithium and mood stabilizers are only
seen after chronic administration; therefore the search
for their mechanism of action should not be based
on acute biochemical effects. In recent years, research
aimed at elucidation of the cellular mechanisms
underlying the therapeutic effects of mood stabilizers
have focused on their chronic action on second-
messenger generating systems (Manji et al., 1995,
1996).
Numerous studies have demonstrated that the
cAMP second-messenger system is modulated by lith-
ium (Jope and Williams, 1994). In general, these show
that lithium increases basal levels of cAMP but im-
pairs receptor-coupled stimulation of cAMP pro-
duction. These dual effects of lithium might be due to
inhibition by lithium of the G proteins that mediate
cAMP production. Receptor-mediated production of
cAMP is controlled by a stimulatory G protein (Gs),
and a counter-balancing inhibitory G protein (Gi).
Under basal conditions, cAMP production is tonically
inhibited by the prevailing Gi influence. Increased
basal cAMP levels caused by lithium may occur at
least in part because lithium reduces the activity of
Gi (Masana et al., 1992), apparently by shifting its
equilibrium between a free active conformation and
an inactive heterotrimeric conformation towards the
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inactive form. Therefore, inhibitory effects of lithium
on Gi can elevate the basal level of cAMP. On the other
hand, attenuation of stimulus-induced increases in
cAMP production, such as by norepinephrine, may be
caused by an inhibitory effect of lithium on the acti-
vation of Gs, through an as yet unspecificied mechan-
ism. Overall, it appears that these actions of lithium
reduce the magnitude of fluctuations in cAMP levels
by increasing the lowest basal levels and decreasing
maximal stimulated increases, thus stabilizing the
activity of this signalling system.
In the last 10 yr the main focus of the research on
the molecular mechanisms underlying the therapeutic
effects of lithium has been the receptor-coupled hy-
drolysis of phosphatidyl inositol 4,5-biphosphate
(PIP2). Activation of receptors coupled to phospha-
tidyl inositol hydrolysis results in the breakdown of
phosphoinositide 4,5-biphosphate (PIP2) into two se-
cond messengers: IP3 and diacylglycerol (DAG),
which is an endogenous activator of protein kinase C
(PKC). Lithium, at therapeutically relevant concen-
trations, is an uncompetitive inhibitor of inositol
monophosphatase (Ki=0.8 mM) and results in an ac-
cumulation of inositol 1-monophosphate as well as a
reduction in free inositol specifically in those cells
undergoing the highest rate of PIP2 hydrolysis (for a
review see Shaldubina et al., 2001). It was proposed
that the physiological consequence of lithium’s action
is derived through a depletion of free inositol and that
its selectivity could be attributed to its preferential
action on the most overactive receptor-mediated
neuronal pathways. Following these observations it
was hypothesized that lithium’s action derived
through a depletion of free myoinositol in the brain,
the so-called ‘inositol depletion hypothesis ’. It was
proposed that this action might result in the depletion
of inositol-containing lipids thereby attenuating re-
ceptor-coupled phosphoinositide signalling. Despite
the difficulty in demonstrating that lithium treatment
reduces resynthesis of PIP2 in all cell systems, a body
of preclinical data, however, suggests that some of
the initial actions of lithium may occur with a relative
depletion of myoinositol initiating then a cascade of
secondary changes at different levels of the signal
transduction process and gene expression in the CNS,
effects that are ultimately responsible for lithium’s
therapeutic efficacy (Jope, 1999; Manji et al., 1995).
Since lithium has been shown to interact with
the two major receptor G protein-coupled signalling
pathways, studies have examined the direct effects of
lithium on G protein activity. Although some studies
have reported modest changes in the levels of G
protein subunit, several independent laboratories
have reported that chronic lithium does not modify
G-protein levels per se, but clearly modifies G protein
function. Recent studies have also examined the effects
of long-term lithium administration on G protein
function in humans and have generally observed re-
duced receptor/G protein coupling (Li et al., 2000).
The final target of second-messenger transduction
systems is the activity protein kinases (PKA, PKC)
(Casebolt and Jope, 1991). A primary action of cAMP
is to stimulate the activity of cAMP-dependent PKA.
Several studies found that lithium can modulate
stimulated PKA-mediated protein phosphorylation.
Using a purified system, Mori et al. (1996) have dem-
onstrated that the phosphotransferase activity of PKA
can be directly inhibited by therapeutic concentrations
of lithium salts. Moreover chronic lithium treatment
resulted in a significant increase in cAMP binding, as
well as in the levels of the PKA subunits in the soluble,
but not in the particulate fractions of different brain
areas (Mori et al., 1998).
Lithium’s effects on signalling processes down-
stream from phosphoinositide hydrolysis have also
been studied extensively, and many reports describe
the modulation of PKC by lithium. PKC exists as a
family of closely related subspecies, has a hetero-
geneous distribution in the brain (with particularly
high levels in presynaptic nerve terminals), and plays
a major role in the regulation of neuronal excitability,
neurotransmitter release, and long-term alterations
in gene expression and plasticity (Stabel and Parker,
1991). Short-term lithium treatment may activate PKC,
whereas long-term lithium exposure results in an at-
tenuation of phorbol ester-mediated responses, which
may be accompanied by down-regulation of PKC iso-
zymes in the brain (Manji et al., 1996). One of the major
substrates of PKC, myristoylated alanine-rich C kinase
substrate (MARCKS), has been studied extensively
and lithium was found to reduce the levels of
MARCKS, an effect that is also caused by direct acti-
vation of PKC, suggesting a modulatory effect of lith-
ium on PKC activity which modulates MARCKS.
MARCKS is involved in cytoskeletal architecture, in-
dicating that this function may be affected by lithium
(Lenox et al., 1992, see Table 1).
Second-messenger mediated pathways represent
the target of lithium, it has therefore been of interest to
test whether other putative mood-stabilizing agents
exert similar effects on the same signalling pathways.
Considerable data suggest that CBZ and VPA are an
alternative or adjunctive treatment to lithium, both for
acute manic episodes as well as for long-term prophy-
laxis in bipolar affective disorder (Brambilla et al.,
2001). However the cellular mechanisms underlying
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both the anticonvulsant and mood-stabilizing effects
of CBZ and VPA have not yet been completely
identified.
CBZ is chemically related to the tricyclic anti-
depressants. Widely used in the treatment of partial
and generalized tonic-clonic seizures, CBZ has been
reported to stabilize the inactive form of the Na+
channel in a voltage-, frequency-, and time-dependent
fashion. Inhibition of glutamatergic neurotrans-
mission has also been implicated in the mechanism of
CBZ action. Recent evidence suggests that it inhibits
the rise in intracellular-free Ca2+ induced by NMDA
and glycine in rat cerebellar granule cells and blocks
veratridine-induced release of endogenous glutamate
(Kwan et al., 2001). CBZ does not affect the PKC-
signalling pathway or G proteins, however, it pro-
duces many effects on the cAMP-signalling pathway.
CBZ decreases the basal concentrations of cAMP in
the mouse cerebral cortex and cerebellum and reduces
cAMP production induced by norepinephrine and
adenosine. Moreover it has been recently reported that
CBZ inhibits both basal and forskolin-stimulated
activity of purified adenylate cyclase (AC). These data
suggest that CBZ inhibits cAMP production by acting
directly on AC and/or through factors tightly associ-
ated with or co-purified with AC (Chen et al., 1996).
Consistent with these results, it has been demon-
strated that CBZ attenuates forskolin-induced c-fos
(an immediate-early gene) expression and inhibits
forskolin-induced phosphorylation of CREB. Because
c-fos and CREB are known to be involved in mediating
a number of long-term neuronal responses, these ef-
fects might be postulated to play a role in the delayed
therapeutic effect of CBZ.
Sodium valproate has proved to be an extremely
useful anti-epileptic drug, with a broad spectrum of
activity and particular efficacy in the generalized epi-
lepsies, however the precise mechanisms by which
it exerts its anti-epileptic as well as mood-stabilizing
effects remain to be determined. VPA has been re-
ported to block voltage-dependent Na+ channels and
to reduce sustained repetitive firing of neurons in
culture. There is evidence to suggest that VPA elevates
whole brain GABA levels and potentiates GABA
responses, possibly by enhancing GAD activity and
inhibiting GABA degradation (Lo¨scher, 1999). Anec-
dotal reports suggest that the drug also augments
GABA release and blocks GABA uptake. Some studies
have suggested that VPA causes decreased excitatory
transmission in the brain by reducing the number
of action potentials elicited by application of NMDA.
VPA would then exert its mood-stabilizing effect
through preventing hyperexcitability in membranes
via inhibiting voltage-activated sodium channels, its
action on excitatory neurotransmitters, or its various
GABAergic actions (Johannessen, 2000).
Following the idea that drugs belonging to the same
therapeutic class (e.g. anti-manic agents) even if pos-
sessing distinct chemical structures, may share com-
mon biochemical targets when administered in a
‘therapeutically relevant’ paradigm, the effects of
VPA on second-messenger pathways have been in-
vestigated. In view of the significant effects of lithium
on PKC, it has been found that VPA even if structur-
ally unrelated, produces effects on the PKC signalling
pathway that are strikingly similar to those of lithium
(Chen et al., 1994; Watson et al., 1998). Long-term ad-
ministration of lithium and VPA seems to regulate
PKC isozymes by distinct mechanisms and VPA’s
effects seem to be largely independent of myoinositol.
This biochemical observation is consistent with clini-
cal observations that some patients have a preferential
Table 1. Main effects of lithium on signal transduction
mechanisms
Adenylyl cyclase
Increased basal levels of cAMP
Decreased receptor stimulated levels of cAMP
Phosphatidylinositol cycle
Uncompetitive inhibition of inositol monophosphatase
Accumulation of inositol 1-monophosphate
Reduction in free inositol
G proteins
Attenuation of receptor-stimulated adenylyl cyclase
activity
Attenuation of receptor-mediated and GTPc S-mediated
phosphoinositide turnover
Attenuation of agonist-induced [3H]GTP binding
Reversal of the effect of lithium by increasing GTP
Increase in pertussis toxin-catalysed [32P]ADP ribosylation
in platelets and in rat brain
Reduction in Gas, Gai1, Gai2 mRNA in rat cortex
Protein kinases
In-vitro inhibition of PKA catalytic subunit
Increased cAMP binding to PKA regulatory subunit and
increased levels of R and C subunit after chronic
treatment in the rat
Short-term activation and long-term attenuation of phorbol
ester-mediated neurotransmitter release
Reduced in-vitro PKC-mediated phosphorylation of major
PKC substrates
Reduced [3H]PDBU binding in hippocampal structures,
CA1 and subiculum
Reduced immunolabelling of PKCa, PKCe, and MARCKS
in rat hippocampus and culture cells
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response to one or the other agent and that additive
therapeutic effects often occur when the two agents
are co-administered.
Neurobiology of mood disorders
Early biological theories regarding the pathophysi-
ology of bipolar disorders have focused on various
neurotransmitters, in particular, the biogenic amines.
The behavioural and physiological manifestations of
bipolar disorders are complex and undoubtedly
mediated by a network of interconnected neuronal
circuits and it is thus not surprising that the brain
systems which have received the greatest attention
in neurobiological studies of mood disorders have
been the monoamines since they are extensively dis-
tributed throughout the network of limbic, striatal
and prefrontal cortical neuronal circuits thought to
support the behavioural and visceral manifestations
of mood disorders. Assessments of CSF chemistry,
neuroendocrine responses to pharmacological chal-
lenge and neuroreceptor binding have demonstrated
a number of abnormalities of the serotonergic, nor-
adrenergic and other neurotransmitter and neuropep-
tide systems in mood disorder (Garlow et al., 1999).
The observations that clinical effects of mood stabil-
izers are only observed after chronic (days to weeks)
administration and that regulation of cellular signal-
ling transduction pathways play a major role in the
therapeutic effects of lithium and mood stabilizers,
have led to the agreement that while dysfunction
within the monoaminergic neurotransmitter systems
is likely to play important roles in mediating some
aspects of the pathophysiology of mood disorders, it
probably represents the epiphenomena of more pri-
mary abnormalities (Manji and Lenox, 2000; Manji
et al., 2001). Thus the most recent research into the
pathophysiology and treatment of bipolar disorders
has focused on intracellular signalling pathways
(Vawter et al., 2000).
Studies of receptor and post-receptor function in
mood disorders have been limited to indirect strat-
egies, such as characterization of receptor function in
readily accessible blood elements.
Among these pathways, the upstream components
of cAMP signalling have been extensively investi-
gated. In particular, a large number of studies has
demonstrated alterations in the levels and function
of Gas and Gai, as well as in the activity of AC and
PKA-mediated phosphorylation in peripheral cells
and the post-mortem brain of patients with affective
disorders (Perez et al., 1999, 2000; Warsh and Li, 1996;
Warsh et al., 2000; Zanardi et al., 1997). In view of the
indirect evidence for abnormalities at post-receptor
sites, it is not surprising that several independent
laboratories have examined G proteins in patients
with mood disorders. Increased levels of Gas as well
as increases in forskolin-stimulated AC activity have
been described in post-mortem brains of bipolar
patients (Young et al., 1993).
Despite the clear role of modulation of PKC activity
in the mechanism of action of mood stabilizers, there
have only been a limited number of studies directly
examining PKC in bipolar patients (Jope et al., 1996;
Soares and Mallinger, 1997). When measuring PKC
isozyme levels, activity, and translocation in post-
mortem brain tissue from bipolar patients, Wang
and Friedman (1996) reported increased PKC activity
and translocation in bipolar disorder brains, compared
to control subjects, effects that were accompanied
by elevated levels of selected PKC isozymes in cortices
of bipolar disorder subjects.
Beyond second messengers
Any relevant biochemical models proposed for the
effects of mood stabilizers must account for their
special temporal clinical profile; patterns of effects re-
quiring prolonged administration of the drug suggest
alterations at the genomic level. The putative effects
of mood stabilizers on gene expression have been
recently investigated by examining their effects on
the DNA-binding activity of transcription factors, es-
pecially the AP-1 family of transcription factors (Chen
et al., 1997; Chen et al., 1999c; Ozaki and Chuang,
1997; Yuan et al., 1998). AP-1 is a collection of homo-
dimeric and heterodimeric complexes composed of
products from two transcription factor families, Fos
and Jun. These products bind to a common DNA site
(known as the TPA response element) in the regulat-
ory domain of the gene and activate gene transcription
in response to PKC activators, growth factors, cyto-
kines, and other agents (including neurotransmitters).
The genes known to be regulated by the AP-1 family
of transcription factors in the brain include genes
for various neuropeptides, neurotrophins, receptors,
transcription factors, enzymes involved in neuro-
transmitter biosynthesis, and proteins that bind to
cytoskeletal elements. It has recently been demon-
strated that both lithium and VPA, at therapeutically
relevant concentrations, produce a time- and concen-
tration-dependent increase in the AP-1 DNA-binding
activity that translates into changes at the gene
expression level (Asghari et al., 1998).
The precise mechanism by which lithium and
VPA regulate AP-1 DNA binding activity remains
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to be fully delineated, but may involve effects on
mitogen-activated protein (MAP) kinases. PKC acti-
vates certain MAP kinases, which phosphorylate
c-Jun thus enhancing the formation of the active AP-1
complex (Figure 1).
Interestingly it has recently been demonstrated that
lithium as well as VPA inhibit the activity of a specific
kinase, glycogen synthase kinase 3b (GSK-3b) (Chen
et al., 1999d; Stambolic et al., 1996; Williams and
Harwood, 2000). GSK-3b plays an important role in
the CNS by regulating various cytoskeletal processes
through its effects on Tau and Synapsin I and by in-
ducing long-term nuclear events through phosphoryl-
ation of c-Jun and nuclear translocation of b-catenin.
GSK-3b is known to phosphorylate c-Jun at sites ad-
jacent to the DNA binding domain, thereby reducing
AP-1 binding. Thus, the acute inhibition of GSK-3b
by lithium and VPA has the potential to bring about
long-term changes in the CNS through the transcrip-
tional activity of both b-catenin and AP-1 (Figure 1).
Unlike many protein kinases, GSK-3b is highly ac-
tive in resting cells and is primarily regulated by
inactivation. Several recent studies have found that
inhibition of GSK-3b by lithium reduces the phos-
phorylation of microtubule associated protein (MAPs)
such as tau and MAP-1B (Hong et al., 1997). The intra-
cellular neurofibrillary tangles found in Alzheimer’s
disease are composed of straight and paired helical
filaments that contain an aberrantly hyperphospho-
rylated form of the MAP, tau. Even if GSK-3b is only
one of the kinases involved in phosphorylating tau,
inhibition of GSK-3b by lithium may reduce levels of
hyperphosphorylated tau.
By acting on transcription factors, mood-stabilizing
drugs have the potential to regulate the expression
of a number of critical genes in the CNS (Manji
et al., 1999a). One of the genes whose expression is
markedly increased by lithium and VPA treatments
encodes another transcription factor, the b-subunit
of the polyomavirus enhancer-binding protein 2
(PEBP2b), involved in the regulation of the major
neuroprotective protein Bcl-2 (B-cell lymphoma/leu-
kaemia 2). Chronic treatment of rodents with thera-
peutic doses of lithium and VPAwas found to produce
Rs Ri
Gs Gi
AC
ATP cAMP PIP2
Rq
TrK
R
βγ
Gα
Ras, Rac
MAPKK
MAPK
P P
63/73
transcription
c-Jun c-fos
239/243/249Li, VPA
DAGIP3
PLCβ
Gq/II
Li, CBZ, VPAMg++
PKA
P P
119/133 115/129
transcription
Li, VPA
GSK-3β
RSK
PKCCa++
CREB CREB
Figure 1. Effect of mood stabilizers on signalling pathways and gene transcription mediated by AP-1. In addition to regulating
the activity of b-catenin, GSK-3b also regulates other transcription factors. Two important factors are Jun and cAMP
response-element-binding protein (CREB). GSK-3 phosphorylation of Jun inhibits its binding to DNA, and because Jun is
a subunit of activator protein-1 (AP-1), this can explain why lithium promotes AP-1 activity in human neuronal cell lines.
By contrast, GSK-3b phosphorylation of CREB activates gene expression. CREB also requires phosphorylation by the
cAMP-dependent protein kinase (PKA), an enzyme regulated through adenylate cyclase coupled receptors. These receptors
are a major target of antidepressants and provide a possible mechanism by which lithium could enhance the effects of these
drugs. (Adapted from Chen et al., 1999a.)
186 N. Brunello and F. Tascedda
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/article-abstract/6/2/181/719874 by guest on 18 February 2020
a doubling of Bcl-2 levels in the frontal cortex, an effect
accompanied by a marked increase in the number of
Bcl-2 immunoreactive cells in frontal cortex layers II
and III (Manji et al., 2000a). Moreover, lithium has
very recently been demonstrated to reduce the levels
of the pro-apoptotic protein p53 (Chen and Chuang,
1999). Thus, overall the data clearly shows that chronic
lithium robustly increases the levels of the neuro-
protective protein Bcl-2 and at least in cultured cell
systems, reduces the levels of the pro-apoptotic pro-
tein p53. These data suggest that mood-stabilizer
treatment should result in neuroprotective effect
(Manji et al., 1999b, 2000b; Chuang et al., 2002).
Consistent with these neuroprotective effects, lith-
ium has been shown to increase grey-matter volume
in bipolar patients (Moore et al., 2000a), to increase
the levels of N-acetyl-aspartate, a putative marker
of neuronal viability, in bipolar patients and healthy
volunteers (Moore et al., 2000b), and to enhance
neurogenesis in the rat hippocampus (Chen et al.,
2000). Lithium has also been demonstrated to exert
robust effects against diverse insults both in vivo
and in vitro, including the robust inhibition of brain
infarct volume and neuronal death by lithium pre-
treatment in rodent models of CNS disease (Nonaka
and Chuang, 1998).
In this context it is of note that recent neuroimaging
studies have demonstrated significant reductions in
regional CNS volume and cell numbers (both neurons
and glia), findings that are complemented by post-
mortem observations of cell atrophy and loss (Drevets
et al., 1999; Drevets, 2000). It is still unclear whether
these findings represent neurodevelopmental abnor-
malities, disease progression that fundamentally in-
volves loss of glia and neurons, or the sequelae of the
biochemical changes accompanying repeated affective
episodes per se.
Several studies have been undertaken to unravel the
molecular mechanisms underlying the neurotrophic
and neuroprotective effects of lithium and VPA. It
is widely accepted that several endogenous growth
factors exert many of their neurotrophic effects via
the MAP kinase signalling cascade, known to play an
important role in mediating long-term neuroplastic
events. Recent studies have demonstrated that both
lithium and VPA activate the ERK MAP kinase cas-
cade, which may contribute to the long-term changes
in synaptic plasticity and morphology that follow
chronic treatment (Yuan et al., 2001). One target of
the MAP kinase cascade is the phosphorylation of
CREB, which leads to increased expression of the
anti-apoptotic factor Bcl-2. Together, the regulation
of different signalling pathways brings about an
enhancement of synaptic connectivity potentially
necessary for long-term stabilization of mood.
In conclusion it is becoming more and more evident
that rather than looking for a single site of action, many
different actions should be integrated to obtain a co-
hesive picture of how neuronal function is modulated
by long-term exposure to mood stabilizers. Lithium
and mood stabilizers modulate excitatory and inhibi-
tory synapses and adjust signalling activities regulat-
ing second messengers, transcription factors, and gene
expression. Multiple actions may be necessary because
lithium has anti-manic, antidepressant, and prophy-
lactic stabilizing actions, and because bipolar disorder
is a complex illness involving multiple systems.
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